Eli Lilly surges on earnings beat and raised guidance, driven by strong demand for Mounjaro and Zepbound.
Stock Earnings Results
April 30, 2026
Table of Contents
April 30, 2026
Shares of Eli Lilly and Company (NYSE: LLY) rose 6.11% after the company reported stronger-than-expected first-quarter 2026 results and raised its full-year financial guidance.
Eli Lilly is a pharmaceutical company focused on medicines across diabetes, obesity, oncology, immunology, and neuroscience.
The company reported non-GAAP EPS of $8.55, above estimates of $7.06, representing a 21.1% earnings surprise and 55.5% growth. Revenue came in at $19.80 billion, above estimates of $17.78 billion. Revenue increased 56% year-over-year, driven primarily by volume growth from Mounjaro and Zepbound.
The strongest catalyst was the company’s updated 2026 outlook.
Eli Lilly raised full-year revenue guidance to a range of $82.0 billion to $85.0 billion and increased non-GAAP EPS guidance to $35.50 to $37.00.
Guidance raises often carry more weight than the reported quarter because they reset investor expectations for future earnings power.
Lilly’s growth remains heavily tied to demand for its GLP-1 franchise.
Key Products revenue reached $13.4 billion in the quarter, led by Mounjaro and Zepbound. U.S. revenue increased 43%, while revenue outside the U.S. rose 81%, with Mounjaro driving much of the international volume growth.
This keeps investor focus on manufacturing capacity, pricing, and global demand for obesity and diabetes treatments.
Profit growth outpaced revenue growth during the quarter.
Reported EPS rose 170% to $8.26, while non-GAAP EPS increased 156% to $8.55. Net income rose to $7.4 billion from $2.8 billion in the prior-year period.
That level of earnings acceleration suggests the market is rewarding not just drug demand, but improved profit conversion.
The company also highlighted U.S. FDA approval of Foundayo for adults with obesity or overweight with weight-related medical problems.
The approval strengthens Lilly’s position in the GLP-1 market by adding an oral option, which could expand access beyond injectable treatments.
Investors are likely to focus on whether Lilly can sustain growth across three areas:
The key tension is clear: volume growth remains powerful, but lower realized prices are already offsetting part of the revenue increase.
Eli Lilly’s quarter shows why earnings reactions are often driven by guidance revisions, not just reported results.
The stock move reflects a combination of estimate beats, stronger full-year expectations, and continued confidence in the company’s obesity and diabetes portfolio.
Platforms like LevelFields track earnings releases alongside activist investor stake, layoffs, corporate events, and dividends, helping investors identify when a company’s earnings report includes multiple signals that can drive repricing.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better investor.
AI scans for events proven to impact stock prices, so you don't have to.
LEARN MORE